David Adler, MD, Ph.D., MBA, explains how earlier collaboration between academic and pharma researchers can strengthen oncology discoveries that lead to clinical trials.
- The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection
- Lupus Researchers Now Have A Three-Pillar RWD Platform To Support Discovery And Development
- Novel Science, Familiar Regulatory Pathways: Inside Tonix's Clinical Development Strategy
- As U.S. Trial Share Slips, A Coalition Maps A Path To Broader Patient Access
- Walmart's Clinical Trial Model Faces Its Real Test
- A Window Into Aging: Why Skin Is the First Test For RLS-1496
- Brazil's Regulatory Transformation: Building And Supporting Sites Beyond The AMCs
GUEST COLUMNISTS
-
A Window Into Aging: Why Skin Is the First Test For RLS-1496
Rubedo’s Marco Quarta explains how patient selection, controls, biopsies, and biomarkers shaped early RLS-1496 trial protocols.
-
Brazil's Regulatory Transformation: Building And Supporting Sites Beyond The AMCs
Our expert chat about Brazil’s clinical research transformation concludes with SBOC President-elect Fabio Franke, who explores building sustainable trial capacity beyond the country’s major AMCs.
-
Brazil's Regulatory Transformation: Expanding Clinical Trial Participation
A discussion of Brazil’s clinical research transformation continues as this Q&A series turns to Maiko L. Tonini, Ph.D., of Brazil’s Ministry of Health, to explore expanding clinical trial participation.
-
Brazil's Regulatory Transformation: A New Era For Clinical Development
Brazil’s clinical research transformation takes center stage as this new Q&A series opens with Interfarma CEO and former ANVISA director Renato Porto.
-
The Real Problem In Patient Recruitment… Is Knowing How And When To Use AI
AI might find patients faster, but only people earn their trust. A site COO explains how to pair AI speed with human judgment, plus the guardrails every site should build in.
-
An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
FDA’s real-time CRL releases face legal and operational hurdles. Could AI-assisted redaction make transparency faster and more consistent?
-
Overcome The 6 Most Common Hurdles To Turning Wearable Data Into Usable RWE
Wearable data is easy to collect but difficult to turn into trusted RWE. Explore six fixes for the most common data problems when using wearables in research.
-
What Happens When Clinical Trial Patients Need Care Outside Of The Study?
Clinical trial patients may need care outside of the trial protocol. Discover how closing information gaps can protect safety, trial participation, and data integrity.
CLINICAL TRIAL WHITE PAPERS
-
Overcome Patient-Level Access Barriers For New Medicine
Explore market access from the patient’s perspective and identify five aspects of how people get hold of medicine that should inform commercialization.
-
Clinical Trial Evaluation And Referral Challenging For Physicians9/24/2026
Physicians often encounter information gaps when evaluating clinical trials for patients. A recent survey indicates a fragmented, confusing trial information landscape that is difficult to navigate.
-
5 Questions To Ask Before Selecting A Randomization Partner5/12/2026
Choose the right IRT partner for complex master protocols. Learn how adaptive randomisation expertise and flexible technology reduce disruption and keep trials execution-ready.
-
Overcoming Issues Of Non-Enrolling Sites In Clinical Trials1/14/2025
Explore the challenges of non-enrolling sites in clinical trials, focusing on the benefits of leveraging artificial intelligence (AI) and machine learning (ML) in addressing those issues.
-
Reducing Inventory Errors In Clinical Trials5/8/2026
Can a digital double-check save your trial from data errors? How does verifying shipments at receipt slash inventory mistakes? Learn to protect protocol integrity and patient safety.
-
De-Risking The Neurology IND: Lessons From Early FDA Engagement5/27/2026
Learn how early FDA alignment can help your neurology program move forward with greater clarity, confidence, and regulatory readiness.
CLINICAL TRIAL APP NOTES & CASE STUDIES
-
Accelerating Enrollment For Direct-To-Patient Observational Studies10/14/2026
Removing the handoff between patient self-screening and enrollment changes what a fully virtual observational study can achieve, from conversion at peak intent to completion rates among participants.
-
Study Analysis – Site Payment Automation12/8/2025
By removing administrative bottlenecks, see how automation improves cash flow for sites, reduces operational burden for sponsors, and supports smoother, more predictable trial execution.
-
Urgent Compliance Recovery Following Vendor Transition5/26/2026
Strong local leadership, clear ownership, and governed oversight drove rapid remediation of legacy safety gaps, restoring regulatory confidence and safeguarding market continuity.
-
Preparing The Next Generation Of Clinical Research Professionals9/4/2025
Explore the live EDC platform that enabled Durham Tech to create a model for future-forward, hands-on education in clinical research.
-
What Unified eCOA And IRT Can Unlock4/6/2026
See how real-time scoring and automated eligibility checks helped a global dermatology study reduce site burden, avoid manual errors, and move participants through screening with greater speed.
-
CRO Takes Trial Build Times From Weeks To Days5/27/2025
Recognizing the inefficiencies in traditional build processes, a top global CRO partnered with Medable to transform its approach to clinical trial launch.
NEWSLETTER ARCHIVE
- 11.10.26 -- AI Saved Time. Employees Didn't Feel It.
- 11.09.26 -- The Site Landscape Is Evolving, But How?
- 11.09.26 -- Cancer Trial Recruitment Isn't Failing On Eligibility — It's Failing On Trust
- 11.07.26 -- Can Psychedelic‑Assisted Treatment Redefine Emotional Care In Oncology?
- 11.06.26 -- Freeing Trial Data Without Losing Trust: AI, Precision Medicine, And Oncology Speed
RECRUITMENT AND DIVERSITY
This section includes some helpful resources regarding patient recruitment and diversity in clinical trials, including this link to the FDA's guidance on diversity action plans.
-
Lupus Nexus unites a registry, biorepository, and data exchange to give researchers longitudinal real-world data without building the infrastructure from scratch.
-
Milken Institute's Kristin Schneeman explains how a new action plan could broaden patient access in the U.S. — and what sponsors and policymakers can do now.
-
AI might find patients faster, but only people earn their trust. A site COO explains how to pair AI speed with human judgment, plus the guardrails every site should build in.
FOCUS ON PATIENTS
-
Milken Institute's Kristin Schneeman explains how a new action plan could broaden patient access in the U.S. — and what sponsors and policymakers can do now.
-
Clinical trial patients may need care outside of the trial protocol. Discover how closing information gaps can protect safety, trial participation, and data integrity.
-
Can early APG-157 treatment control head and neck cancer without delaying curative care? A Phase 3 trial puts timing, safety, and outcomes to the test.
EDITORIAL COLLECTIONS
Take a deep dive into the issues shaping clinical research today with our curated Editorial Collections. Each collection features expert insights and practical strategies addressing today’s biggest challenges in clinical trial planning and execution.
More Editorial Collections
